Cessatech Dirección

Dirección controles de criterios 1/4

El CEO de Cessatech's es Jes Trygved, nombrado en Jan 2020, tiene una permanencia de 4.25 años. posee directamente un 5.19% de las acciones de la empresa, con un valor de DKK5.97M. La antigüedad media del equipo directivo y de la junta directiva es de 0.3 años y 3.7 años, respectivamente.

Información clave

Jes Trygved

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	4.4yrs
Participación del CEO	5.2%
Permanencia media de la dirección	less than a year
Promedio de permanencia en la Junta Directiva	3.8yrs

Actualizaciones recientes de la dirección

Recent updates

CEO

Jes Trygved (51 yo)

4.4yrs

Permanencia

Mr. Jes Trygved serves as Chief Executive Officer at Cessatech A/S (formerly known as Cessatech ApS) since 2020. Mr. Trygved has experience within the biotech and pharmaceutical industry including time spe...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Jes Trygved	Chief Executive Officer	4.4yrs	sin datos	5.23% DKK 5.6m
Martin Juhl	Chief Scientific Officer and Head of CMC	less than a year	sin datos	sin datos
Louise Bak	Head of Regulatory Affairs	2.3yrs	sin datos	sin datos
Malene Cording	Head of Clinical Development & Operations	less than a year	sin datos	sin datos
Mai Gregersen	Head of Quality Assurance	less than a year	sin datos	sin datos

0.5yrs

Permanencia media

Equipo directivo experimentado: El equipo directivo de CESSA no se considera experimentado ( 0.3 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Flemming Jensen	Independent Director	3.8yrs	sin datos	sin datos
Peter Birk	Independent Director	3.8yrs	sin datos	0.059% DKK 63.6k
Martin Olin	Independent Chairman of the Board	3.8yrs	sin datos	1.3% DKK 1.4m
Charlotte Videbaek	Independent Director	3.8yrs	sin datos	0.96% DKK 1.0m
Rachel Gravesen	Director	2.4yrs	sin datos	0.22% DKK 233.6k

3.8yrs

Permanencia media

60.5yo

Promedio de edad

Junta con experiencia: La junta directiva de CESSA se considera experimentada (3.7 años de antigüedad promedio).

Cessatech Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

Cessatech A/S, Annual General Meeting, Mar 27, 2024

Cessatech A/S, Annual General Meeting, Mar 17, 2023

High number of new and inexperienced directors

Cessatech A/S, Annual General Meeting, Mar 26, 2021

Recent updates

Cessatech A/S Reports First Patient Dosed in Final Safety Study 0202 of Lead Product Candidate CT001

Cessatech A/S to Report Q1, 2024 Results on May 15, 2024

New major risk - Negative shareholders equity

Cessatech A/S, Annual General Meeting, Mar 27, 2024

New minor risk - Shareholder dilution

Cessatech A/S Announces the Paediatric Committee Agrees to Reduce the Number of Required Children in the Final Clinical Study with CT001 from 300 to 150 Children

Cessatech A/S to Report Q3, 2023 Results on Nov 16, 2023

Cessatech Announces Last Participant Dosed in Pivotal Trial 0205 with Lead Candidate CT001

Cessatech A/S Announces EMA's Paediatric Committee Agrees to Paediatric Investigational Plan for CT002 for Procedural Sedation

Cessatech A/S to Report Q2, 2023 Results on Aug 24, 2023

Cessatech A/S, Annual General Meeting, Mar 17, 2023

Cessatech A/S to Report Fiscal Year 2022 Results on Mar 03, 2023

High number of new and inexperienced directors

Cessatech Reports Successful Outcome of Pharmacokinetic Trial in Children of Lead Candidate

Cessatech A/S Reports First Patient Dosed in Pivotal Trial of Lead Product Candidate

Cessatech A/S Reports First Patient Dosed in Pivotal Trial of Lead Product Candidate

Cessatech A/S Announces Pivotal Trial 0205 Has Obtained Regulatory Approval

Cessatech Reports Last Patient Dosed in Pharmacokinetic Trial in Children of Lead Candidate

Cessatech Reports Successful Outcome of Bioavailability Trial 0204 with CT001

Cessatech A/S Expects to Report on its Bioavailability Trial 0204 Within Few Weeks

Cessatech Reports First Patient Dosed in Pharmacokinetic Trial in Children of Lead Product Candidate

Cessatech Reports Last Subject Dosed in Bioavailability Trial of Lead Product Candidate

Cessatech A/S, Annual General Meeting, Mar 26, 2021

CEO

Permanencia

Equipo directivo

Permanencia media

Miembros de la Junta

Permanencia media

Promedio de edad